A Study to Learn About Safety and Effects of Once-monthly Treatment With Berobenatide in Adults With Obesity Disease in Japan (VESPER-JM)

Change from baseline in waist circumference

Time frame: Baseline, Week 72

Percentage of participants achieving ≥10% of body weight reduction from baseline

Time frame: Baseline, Week 72

Percentage of participants achieving ≥15% of body weight reduction from baseline

Time frame: Baseline, Week 72

Percentage of participants achieving ≥20% of body weight reduction from baseline

Time frame: Baseline, Week 72

Percentage of participants achieving ≥5% of body weight reduction from baseline

Time frame: Baseline, Week 72

Change from baseline in body weight

Time frame: Baseline, Week 72

Change from baseline in Systolic Blood Pressure (SBP)

Time frame: Baseline, Week 72

Change from baseline in Diastolic Blood Pressure (DBP)

Time frame: Baseline, Week 72

Change from baseline in Impact of Weight on Quality of Life-Lite-Clinical Trial (IWQoL-Lite-CT) Physical Function composite score

Time frame: Baseline, Week 72

Change from baseline in IWQoL-Lite-CT total score

Time frame: Baseline, Week 72

Change from baseline in IWQoL-Lite-CT Physical composite score

Time frame: Baseline, Week 72

Change from baseline in IWQoL-Lite-CT Psychosocial composite score

Time frame: Baseline, Week 72

Change from baseline in fasting glucose

Time frame: Baseline, Week 72

Change from baseline in fasting insulin

Time frame: Baseline, Week 72

Change from baseline in revised Homeostatic Model Assessment insulin sensitivity as a percentage of normal (HOMA2-%S)

Time frame: Baseline, Week 72

Change from baseline in revised Homeostatic Model Assessment beta-cell function as a percentage of a normal reference population (HOMA2-%B)

Time frame: Baseline, Week 72

Change from baseline in HbA1c

Time frame: Baseline, Week 72

Change from baseline in fasting total cholesterol

Time frame: Baseline, Week 72

Change from baseline in fasting low-density lipoprotein cholesterol

Time frame: Baseline, Week 72

Change from baseline in fasting very low-density lipoprotein cholesterol

Time frame: Baseline, Week 72

Change from baseline in fasting non-high-density lipoprotein cholesterol

Time frame: Baseline, Week 72

Change from baseline in fasting high-density lipoprotein cholesterol

Time frame: Baseline, Week 72

Change from baseline in fasting triglycerides

Time frame: Baseline, Week 72

Change from baseline in high-sensitivity C-reactive protein

Time frame: Baseline, Week 72

Change from baseline in interleukin-6

Time frame: Baseline, Week 72

Change from baseline in interleukin-1 beta

Time frame: Baseline, Week 72

Number of participants with Treatment Emergent Adverse Events (TEAEs)

Time frame: Week 72

Number of participants with Serious Adverse Events (SAEs)

Time frame: Week 72

Number of participants with adverse events leading to discontinuation

Time frame: Week 72

Number of participants with Adverse Events of Special Interest (AESIs)

Time frame: Week 72

Number of participants with absolute and change from baseline in laboratory measurements

Time frame: Week 72

Change from baseline in visceral fat area

Time frame: Baseline, Week 72

Percentage of participants achieving visceral fat area <100 cm2

Time frame: Week 72

Percentage of participants achieving the conversion to normoglycemia

Time frame: Week 72

Change from baseline in Oral Glucose Tolerance Test (OGTT) 2h

Time frame: Baseline, Week 72

Percentage of participants achieving conversion from HbA1c ≥7% to HbA1c <7%

Time frame: Week 72

Percentage of participants achieving conversion from HbA1c ≥5.7% to HbA1c <5.7%

Time frame: Week 72